Efficacy of entecavir monotherapy in nucleoside-naive patients with chronic hepatitis B in a tertiary clinic setting

被引：0
|
作者：
Davison, S. A. [1 ]
Dobbins, T. A. [1 ]
Segaert, N. [1 ]
Koorey, D. J. [1 ]
Shackel, N. A. [1 ]
Bye, W. A. [1 ]
Selby, W. S. [1 ]
McCaughan, G. W. [1 ]
Strasser, S. I. [1 ]
机构：
[1] Royal Prince Alfred Hosp, AW Morrow Gastroenterol & Liver Ctr, Camperdown, NSW 2050, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2009年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A282 / A282
页数：1
相关论文
共 50 条
  • [41] Entecavir demonstrates superior histologic and virologic efficacy over lamivudine in nucleoside-naive HBeAg(-) chronic hepatitis B: Results of phase III trial ETV-027.
    Shouval, D
    Lai, CL
    Cheinquer, H
    Lok, A
    DeHertogh, D
    Wilber, R
    Cross, A
    Zink, R
    Fernandes, L
    HEPATOLOGY, 2004, 40 (04) : 728A - 728A
  • [42] COMPARISON OF TREATMENT EFFICACY OF CLEVUDINE TO ENTECAVIR FOR ANTIVIRAL NAIVE CHRONIC HEPATITIS B PATIENTS
    Kim, S. B.
    Song, I. H.
    Lee, H. I.
    Yang, H. Y.
    Kim, A. N.
    Chae, H. B.
    Lee, S. H.
    Kim, H. S.
    Lee, T. H.
    Kang, Y. W.
    Lee, E. S.
    Kim, S. H.
    Lee, B. S.
    Lee, H. Y.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S291 - S291
  • [43] Virologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter study
    Yao, Guangbi
    Chen, ChengWei
    Lu, WeiLun
    Ren, Hong
    Tan, DeMing
    Wang, YuMing
    Xu, DaoZheng
    Liu, Jessica
    Xu, Dong
    Llamoso, Cyril
    HEPATOLOGY INTERNATIONAL, 2008, 2 (04) : 486 - 493
  • [44] ENTECAVIR RESISTANCE IN ENTECAVIR NAIVE LAMIVUDINE TREATED CHRONIC HEPATITIS B PATIENTS
    Sayan, Murat
    Hulagu, Sadettin
    Akhan, Sila Cetin
    Senturk, Omer
    Meric, Meliha
    Cekmen, Mustafa
    MIKROBIYOLOJI BULTENI, 2009, 43 (03): : 425 - 432
  • [45] Entecavir (ETV) is well tolerated for the treatment of nucleoside-naive and Lamivudine-refractory chronic hepatitis B: phase 2/3 safety results
    Gigi, M. R.
    Manns, M.
    Cooney, E.
    Hindes, R.
    Cross, A.
    Wilber, R.
    LIVER INTERNATIONAL, 2006, 26 : 56 - 56
  • [46] Long-term outcomes of entecavir monotherapy in patients with treatment-naive chronic hepatitis B
    Kim, Hyung Joon
    Lee, Hyun Woong
    Park, Ji Hoon
    Lee, Kyeong Heon
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 248 - 249
  • [47] Hepatitis B virus resistance to entecavir in nucleoside naive patients: Does it exist?
    Zoulim, Fabien
    HEPATOLOGY, 2006, 44 (06) : 1404 - 1407
  • [48] Entecavir (ETV) is superior to lamivudine (LVD) for the treatment of chronic hepatitis B (CHB): results of a phase 3 Chinese study (ETV-023) in nucleoside-naive patients
    Yao, Guangbi
    Chen, Chengwei
    Lu, Weilun
    Ren, Hong
    Tan, Deming
    Wang, Yuming
    Xu, Daozheng
    Liu, Jessica
    Xu, Dong
    Macdonald, Laurie
    Jiang, Michael
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A126 - A126
  • [49] IMPACT OF ENTECAVIR VERSUS LAMIVUDINE ON HEPATIC COVALENTLY CLOSED-CIRCULAR DNA AND TOTAL HEPATIC HBVDNA IN NUCLEOSIDE-NAIVE HBeAg POSITIVE CHRONIC HEPATITIS B PATIENTS
    Bowden, S.
    Locarnini, S.
    Chang, T. -T.
    Chao, Y. -C.
    Han, K. -H.
    Gish, R. G.
    de Man, R.
    Llamoso, C.
    Tang, H.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S308 - S309
  • [50] Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naive Patients Is Rare Through 5 Years of Therapy
    Tenney, Daniel J.
    Rose, Ronald E.
    Baldick, Carl J.
    Pokornowski, Kevin A.
    Eggers, Betsy J.
    Fang, Jie
    Wichroski, Michael J.
    Xu, Dong
    Yang, Joanna
    Wilber, Richard B.
    Colonno, Richard J.
    HEPATOLOGY, 2009, 49 (05) : 1503 - 1514
12345